Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535680 | 0.95 | KDM4E (0.51) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12940320 | 0.91 | PTGS2 (0.55) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4790830 | 0.86 | PTGS2 (0.54) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2297483 | 0.86 | PTGS2 (0.50) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4790814 | 0.86 | PTGS2 (0.56) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3396085 | 0.86 | PTGS2 (0.58) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12940051 | 0.86 | KDM4E (0.52) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4792138 | 0.85 | PTGS2 (0.49) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3539094 | 0.85 | MEN1 (0.55) | PTGS2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2297611 | 0.85 | ATM (0.43) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012058125-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | PTGS2 3629/4885KDM4E 3905/4885MEN1 4815/4885 |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, LIPC, HCCS | PTGS2 3629/4885KDM4E 3905/4885MEN1 4815/4885 |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | PTGS2 3629/4885KDM4E 3905/4885MEN1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.